OKN4395
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for OKN4395, covering 2025-09-05 to 2025-09-05. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors [Phase 1]